Sumitomo Mitsui DS Asset Management Company Ltd Acquires 65,243 Shares of Charles River Laboratories International, Inc. $CRL

Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3,726.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,994 shares of the medical research company’s stock after acquiring an additional 65,243 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Charles River Laboratories International were worth $19,764,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CRL. Continuum Advisory LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $30,000. IFP Advisors Inc increased its position in shares of Charles River Laboratories International by 182.8% in the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares during the last quarter. Activest Wealth Management increased its position in shares of Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the last quarter. SHP Wealth Management bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $85,000. Finally, Hilltop National Bank raised its stake in Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 127 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Victoria Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 91,971 shares of company stock valued at $26,033,968 over the last 90 days. Company insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CRL. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price for the company. in a research report on Monday, July 20th. TD Cowen boosted their price target on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Finally, Barclays raised their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the company an “overweight” rating in a research report on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $302.33.

Charles River Laboratories International Trading Up 5.6%

Shares of CRL stock opened at $316.95 on Wednesday. The business has a 50-day moving average price of $290.67 and a two-hundred day moving average price of $230.05. Charles River Laboratories International, Inc. has a 12-month low of $146.20 and a 12-month high of $333.30. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The firm has a market cap of $15.13 billion, a P/E ratio of -65.35, a price-to-earnings-growth ratio of 2.80 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.